Form 8-K - Current report:
SEC Accession No. 0001213900-20-010060
Filing Date
2020-04-24
Accepted
2020-04-24 17:15:12
Documents
5
Period of Report
2020-04-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea120946-8k_actiniumpharma.htm 8-K 27839
2 UNDERWRITING AGREEMENT, DATED AS OF APRIL 21, 2020, BY AND BETWEEN ACTINIUM PHAR ea120946ex1-1_actinium.htm EX-1.1 288080
3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT ea120946ex4-1_actinium.htm EX-4.1 98734
4 OPINION OF THE MATT LAW FIRM, PLLC. ea120946ex5-1_actinium.htm EX-5.1 10640
5 GRAPHIC ex5-1_001.jpg GRAPHIC 8878
  Complete submission text file 0001213900-20-010060.txt   438868
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 20816034
SIC: 2834 Pharmaceutical Preparations